设计的新型核定位抗癌针对p53负调节器MDM2蛋白质
Nabanita Mukherjee1, Debmalya Bhunia2, Prabir Kumar Garai3
1Smart Healthcare, Interdisciplinary Research Platform, Indian Institute of Technology Jodhpur, Karwar, Rajasthan, India.
概括
一种新,mPNC-NLS,针对MDM2蛋白恢复瘤抑制剂p53的活性. 这种有效地诱导癌细胞亡,同时保护正常细胞,提供了一个有前途的新抗癌治疗策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 细胞内蛋白质-蛋白质相互作用是基于的抗癌剂的关键治疗标.
- 瘤基因产物MDM2通过促进瘤抑制剂p53的降解来负面调节瘤抑制剂p53.
- 抑制MDM2-p53相互作用可以恢复p53功能,导致癌细胞亡.
研究的目的:
- 设计和评估一种新,mPNC-NLS,针对MDM2进行癌症治疗.
- 为了研究该的恢复p53活动和诱导癌细胞的亡的能力.
- 在临床前癌症模型中评估的疗效和安全性.
主要方法:
- 设计一种针对核和MDM2蛋白的新 (mPNC-NLS).
- 在A549 (肺) 和U87 (质母细胞瘤) 癌细胞系中亡诱导的体外评估.
- 在正常的肺纤维细胞中评估细胞毒性 (WI38).
- 免疫细胞化学和西部斑点分析以确认p53和p21的激活.
- 对A549细胞3D多细胞球状生长的效应的评估.
主要成果:
- 该mPNC-NLS有效诱导了A549和U87癌细胞中的亡.
- 该对正常的WI38肺纤维细胞细胞没有显著的细胞毒性.
- 西方斑块和免疫细胞化学证实mPNC-NLS激活了p53和p21信号通路.
- mPNC-NLS显著抑制了A549 3D多细胞球体体的体外生长.
结论:
- 新型mPNC-NLS是一种有前途的抗癌剂,可以恢复p53瘤抑制活性.
- mPNC-NLS通过p53/p21激活有效地诱导癌细胞的亡,并抑制瘤生长.
- 该的选择性毒性特征表明,向癌症治疗的潜力是具有减少副作用的.
相关概念视频
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:23Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
01:31The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K